With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

An influential pediatrics group in the U.S. has diverged from the CDC’s recently updated child immunization schedule and ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

O’Reilly Auto Parts will become the title sponsor for NASCAR’s second-tier national series when the Xfinity Series is renamed ...

Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

Architect Levitt Bernstein, in collaboration with low energy specialist Etude, has developed a three-part document package for Greater Manchester Combined Authority, to help applicants comply with the ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...